Oslo,9 November 2019: Ultimovacs ASA (“Ultimovacs”, ticker ULTIMO), a
pharmaceutical company developing novel immunotherapies against cancer, presents
long-term results from a clinical study with UV1 in patients with Non-Small Cell
Lung Cancer (“NSCLC”) during a poster session at the Society for Immunotherapy
of Cancer’s 34th Annual Meeting (SITC 2019) today.

The data is from a UV1 dose finding study in previously treated patients with
advanced stage (III/IV) NSCLC. Eighteen patients were enrolled, with six
patients in each of three different UV1 dose groups (100, 300 and 700µg), with
GM-CSF as adjuvant. Main endpoints were safety, immune response against UV1
peptides and efficacy including long-term survival. 

The main results are:
  • UV1 was well tolerated without any severe safety events
  • UV1 induced a specific immune response in 67% of the patients
  • Median overall survival was 28.2 months
  • Four years overall survival was 39% (7 of 18 patients alive)
  • All results favor the highest UV1 dose (700µg) for this patient population.
In the 700µg dose group, 5 of 6 patients were still alive 4 years after
treatment start
  • None of the long-term survivors have received any other immunotherapy during
the follow-up time
 
Ultimovacs has completed three phase I studies with UV1; in prostate cancer,
malignant melanoma and NSCLC. These three studies have shown clinical outcomes
that Ultimovacs views as a strong basis for further clinical development of UV1.
The NSCLC long-term results presented at SITC today further strengthen this
conclusion.

Detailed results from the study will be presented at SITC 2019 by Professor
Emeritus Gustav Gaudernack. The poster (ID: P342) title is “Long Term Outcome of
a Phase I Study with UV1, a Second-Generation Telomerase based Vaccine in
Patients with Advanced Non-Small Cell Lung Cancer”. The poster is available at
www.ultimovacs.com  

UV1 is a peptide-based vaccine inducing a specific T cell response against the
universal cancer antigen telomerase. UV1 is being developed as a therapeutic
cancer vaccine which may serve as a platform for use in combination with other
immunotherapy which require an ongoing T cell response for their mode of action.



For further information, please see www.ultimovacs.com or contact:

Øyvind Kongstun Arnesen, CEO 
oeyvind.arnesen@ultimovacs.com, +47 469 33 810 

Hans Vassgård Eid, CFO 
hans.eid@ultimovacs.com, +47 469 19 822